Physician profile
Eric Z Berkowitz
NPI 1679670491
$6,940.74
in general payments reported to CMS, 2019-2025
36 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $421 · 2021: $1,032 · 2022: $858 · 2023: $1,524 · 2024: $994 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.21 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,005.67 | 2019-2024 | Xeomin |
| Incyte Corporation | $782.94 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $566.50 | 2019-2025 | Tremfya, Remicade, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $538.35 | 2019-2023 | Jublia |
| Lilly USA, LLC | $473.57 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $441.87 | 2019-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $379.08 | 2019-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $367.21 | 2019-2023 | |
| Leo Pharma INC. | $340.01 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $311.10 | 2019-2025 | |
| Almirall LLC | $164.91 | 2024-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $162.22 | 2022-2025 | Sotyktu |
| Amgen INC. | $157.71 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $144.63 | 2022-2024 | Vtama |
| Genzyme Corporation | $125.47 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $123.21 | 2024-2025 | Zoryve |
| Abbvie INC. | $118.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $94.06 | 2020-2025 | Libtayo, Dupixent |
| Botanix Sb INC | $76.50 | 2025 | Sofdra |
| Journey Medical Corporation | $66.97 | 2022-2025 | |
| Medimetriks Pharmaceuticals, INC. | $52.48 | 2019 | |
| Sebela Pharmaceuticals INC. | $51.66 | 2020-2023 | Pramosone, Naftin |
| Epi Health, LLC | $46.84 | 2022 | |
| Allergan, INC. | $46.77 | 2019-2021 | |
| Organon LLC | $46.27 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $39.38 | 2022-2023 | |
| Ucb, INC. | $28.17 | 2021 | |
| Dermira, INC. | $27.51 | 2019 | |
| Celgene Corporation | $24.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2021 | |
| Dusa Pharmaceuticals, INC. | $22.28 | 2019 | |
| Cipher Pharmaceuticals US LLC | $21.64 | 2025 | Natroba, Spinosad |
| Biosense Webster, INC. | $19.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.10 | 2020 | |
| Merck Sharp & Dohme LLC | $16.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.